UPDRS activity of daily living score as a marker of Parkinson's disease progression.
Identifieur interne : 001B16 ( PubMed/Checkpoint ); précédent : 001B15; suivant : 001B17UPDRS activity of daily living score as a marker of Parkinson's disease progression.
Auteurs : Madaline B. Harrison [États-Unis] ; Scott A. Wylie ; Robert C. Frysinger ; James T. Patrie ; Diane S. Huss ; Lillian J. Currie ; G Frederick WootenSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Activities of Daily Living, Adult, Aged, Aged, 80 and over, Antiparkinson Agents (therapeutic use), Cross-Sectional Studies, Disease Progression, Female, Follow-Up Studies, Humans, Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Psychomotor Performance, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Activities of Daily Living, Adult, Aged, Aged, 80 and over, Cross-Sectional Studies, Disease Progression, Female, Follow-Up Studies, Humans, Male, Middle Aged, Psychomotor Performance, Treatment Outcome.
Abstract
The activities of daily living (ADL) subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) captures the impact of Parkinson's disease (PD) on daily function and may be less affected than other subsections by variability associated with drug cycle and motor fluctuations. We examined UPDRS mentation, ADL and motor subscores in 888 patients with idiopathic PD. Multiple linear regression analyses determined the association between disease duration and UPDRS subscores as a function of medication status at examination and in a subset of patients with multiple examinations. Independent of medication status and across cross-sectional and longitudinal analyses, ADL subscores showed a stronger and more stable association with disease duration than other UPDRS subscores after adjusting for age of disease onset. The association between disease duration and the motor subscore depended on medication status. The strong association between ADL subscore and disease duration in PD suggests that this measure may serve as a better marker of disease progression than signs and symptoms assessed in other UPDRS sections.
DOI: 10.1002/mds.22335
PubMed: 18951537
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:18951537Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">UPDRS activity of daily living score as a marker of Parkinson's disease progression.</title><author><name sortKey="Harrison, Madaline B" sort="Harrison, Madaline B" uniqKey="Harrison M" first="Madaline B" last="Harrison">Madaline B. Harrison</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Virginia, Charlottesville, Virginia 22903, USA. mbh3y@virginia.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Virginia, Charlottesville, Virginia 22903</wicri:regionArea><wicri:noRegion>Virginia 22903</wicri:noRegion></affiliation></author><author><name sortKey="Wylie, Scott A" sort="Wylie, Scott A" uniqKey="Wylie S" first="Scott A" last="Wylie">Scott A. Wylie</name></author><author><name sortKey="Frysinger, Robert C" sort="Frysinger, Robert C" uniqKey="Frysinger R" first="Robert C" last="Frysinger">Robert C. Frysinger</name></author><author><name sortKey="Patrie, James T" sort="Patrie, James T" uniqKey="Patrie J" first="James T" last="Patrie">James T. Patrie</name></author><author><name sortKey="Huss, Diane S" sort="Huss, Diane S" uniqKey="Huss D" first="Diane S" last="Huss">Diane S. Huss</name></author><author><name sortKey="Currie, Lillian J" sort="Currie, Lillian J" uniqKey="Currie L" first="Lillian J" last="Currie">Lillian J. Currie</name></author><author><name sortKey="Wooten, G Frederick" sort="Wooten, G Frederick" uniqKey="Wooten G" first="G Frederick" last="Wooten">G Frederick Wooten</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22335</idno><idno type="RBID">pubmed:18951537</idno><idno type="pmid">18951537</idno><idno type="wicri:Area/PubMed/Corpus">001F65</idno><idno type="wicri:Area/PubMed/Curation">001F65</idno><idno type="wicri:Area/PubMed/Checkpoint">001B16</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">UPDRS activity of daily living score as a marker of Parkinson's disease progression.</title><author><name sortKey="Harrison, Madaline B" sort="Harrison, Madaline B" uniqKey="Harrison M" first="Madaline B" last="Harrison">Madaline B. Harrison</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Virginia, Charlottesville, Virginia 22903, USA. mbh3y@virginia.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Virginia, Charlottesville, Virginia 22903</wicri:regionArea><wicri:noRegion>Virginia 22903</wicri:noRegion></affiliation></author><author><name sortKey="Wylie, Scott A" sort="Wylie, Scott A" uniqKey="Wylie S" first="Scott A" last="Wylie">Scott A. Wylie</name></author><author><name sortKey="Frysinger, Robert C" sort="Frysinger, Robert C" uniqKey="Frysinger R" first="Robert C" last="Frysinger">Robert C. Frysinger</name></author><author><name sortKey="Patrie, James T" sort="Patrie, James T" uniqKey="Patrie J" first="James T" last="Patrie">James T. Patrie</name></author><author><name sortKey="Huss, Diane S" sort="Huss, Diane S" uniqKey="Huss D" first="Diane S" last="Huss">Diane S. Huss</name></author><author><name sortKey="Currie, Lillian J" sort="Currie, Lillian J" uniqKey="Currie L" first="Lillian J" last="Currie">Lillian J. Currie</name></author><author><name sortKey="Wooten, G Frederick" sort="Wooten, G Frederick" uniqKey="Wooten G" first="G Frederick" last="Wooten">G Frederick Wooten</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (therapeutic use)</term><term>Cross-Sectional Studies</term><term>Disease Progression</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Psychomotor Performance</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Cross-Sectional Studies</term><term>Disease Progression</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Psychomotor Performance</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The activities of daily living (ADL) subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) captures the impact of Parkinson's disease (PD) on daily function and may be less affected than other subsections by variability associated with drug cycle and motor fluctuations. We examined UPDRS mentation, ADL and motor subscores in 888 patients with idiopathic PD. Multiple linear regression analyses determined the association between disease duration and UPDRS subscores as a function of medication status at examination and in a subset of patients with multiple examinations. Independent of medication status and across cross-sectional and longitudinal analyses, ADL subscores showed a stronger and more stable association with disease duration than other UPDRS subscores after adjusting for age of disease onset. The association between disease duration and the motor subscore depended on medication status. The strong association between ADL subscore and disease duration in PD suggests that this measure may serve as a better marker of disease progression than signs and symptoms assessed in other UPDRS sections.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18951537</PMID><DateCreated><Year>2009</Year><Month>02</Month><Day>02</Day></DateCreated><DateCompleted><Year>2009</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2014</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>UPDRS activity of daily living score as a marker of Parkinson's disease progression.</ArticleTitle><Pagination><MedlinePgn>224-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22335</ELocationID><Abstract><AbstractText>The activities of daily living (ADL) subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) captures the impact of Parkinson's disease (PD) on daily function and may be less affected than other subsections by variability associated with drug cycle and motor fluctuations. We examined UPDRS mentation, ADL and motor subscores in 888 patients with idiopathic PD. Multiple linear regression analyses determined the association between disease duration and UPDRS subscores as a function of medication status at examination and in a subset of patients with multiple examinations. Independent of medication status and across cross-sectional and longitudinal analyses, ADL subscores showed a stronger and more stable association with disease duration than other UPDRS subscores after adjusting for age of disease onset. The association between disease duration and the motor subscore depended on medication status. The strong association between ADL subscore and disease duration in PD suggests that this measure may serve as a better marker of disease progression than signs and symptoms assessed in other UPDRS sections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Madaline B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Virginia, Charlottesville, Virginia 22903, USA. mbh3y@virginia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wylie</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Frysinger</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Patrie</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Huss</LastName><ForeName>Diane S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Currie</LastName><ForeName>Lillian J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Wooten</LastName><ForeName>G Frederick</ForeName><Initials>GF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 NS039788-05</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-NS39788</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2001 Oct;58(10):1611-5</RefSource><PMID Version="1">11594919</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2002 Mar;17(2):283-8</RefSource><PMID Version="1">11921113</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1994 Jan;9(1):76-83</RefSource><PMID Version="1">8139608</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1996 Mar;11(2):185-92</RefSource><PMID Version="1">8684390</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1998 Jul;13(4):633-6</RefSource><PMID Version="1">9686766</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1999 Mar;56(3):334-7</RefSource><PMID Version="1">10190824</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1999 Sep;67(3):300-7</RefSource><PMID Version="1">10449550</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Clin Pract Neurol. 2009 Mar;5(3):130-1</RefSource><PMID Version="1">19262586</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D000203">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003430">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011597">Psychomotor Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS293159</OtherID><OtherID Source="NLM">PMC3103833</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22335</ArticleId><ArticleId IdType="pubmed">18951537</ArticleId><ArticleId IdType="pmc">PMC3103833</ArticleId><ArticleId IdType="mid">NIHMS293159</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Currie, Lillian J" sort="Currie, Lillian J" uniqKey="Currie L" first="Lillian J" last="Currie">Lillian J. Currie</name><name sortKey="Frysinger, Robert C" sort="Frysinger, Robert C" uniqKey="Frysinger R" first="Robert C" last="Frysinger">Robert C. Frysinger</name><name sortKey="Huss, Diane S" sort="Huss, Diane S" uniqKey="Huss D" first="Diane S" last="Huss">Diane S. Huss</name><name sortKey="Patrie, James T" sort="Patrie, James T" uniqKey="Patrie J" first="James T" last="Patrie">James T. Patrie</name><name sortKey="Wooten, G Frederick" sort="Wooten, G Frederick" uniqKey="Wooten G" first="G Frederick" last="Wooten">G Frederick Wooten</name><name sortKey="Wylie, Scott A" sort="Wylie, Scott A" uniqKey="Wylie S" first="Scott A" last="Wylie">Scott A. Wylie</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Harrison, Madaline B" sort="Harrison, Madaline B" uniqKey="Harrison M" first="Madaline B" last="Harrison">Madaline B. Harrison</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B16 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001B16 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:18951537
|texte= UPDRS activity of daily living score as a marker of Parkinson's disease progression.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:18951537" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |